|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 313.50 EUR | -1.72% |
|
-3.69% | -0.95% |
| Apr. 16 | VIRBAC : Decent Q1; Clarity on US tariff exposure was a key takeaway |  |
| Apr. 16 | VIRBAC : Stifel still buying after Q1 results | CF |
Summary: Virbac
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Virbac
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: Virbac
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings Chart: Virbac
Source: Surperformance
ESG chart: Virbac
Source: MSCI
| Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
|---|---|---|---|---|---|
| 3.09B | |||||
| 75.16B | |||||
| 7.04B | |||||
| 3.61B | |||||
| 2.31B | |||||
| 1.34B | |||||
| - | 1.07B | ||||
| - | 1.01B | ||||
| 995M | |||||
| 993M | |||||
| Average | 9.66B | ||||
| Weighted average by Cap. |
Investor (Composite)
Trader (Composite)
ESG MSCI
AA
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
Valuation
P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
ESG: Environment
ESG: Social
ESG: Governance
ESG: Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
ESG: Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VIRP Stock
- Ratings Virbac
Select your edition
All financial news and data tailored to specific country editions
